Avid Bioservices Names Richard Richieri as Chief Operations Officer
09 Oktober 2019 - 6:30PM
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated
biologics contract development and manufacturing organization
(CDMO) working to improve patient lives by providing high quality
development and manufacturing services to biotechnology and
pharmaceutical companies, today announced the appointment of
Richard (Rich) Richieri as chief operations officer. In this role,
Mr. Richieri will oversee Process Development, Clinical and
Commercial Manufacturing, Technical Support and Facilities.
Mr. Richieri has over 25 years of
biopharmaceutical industry experience spanning the areas of drug
discovery, CGMP operations, contract manufacturing and process
development. Mr. Richieri previously spent 15 years with Avid
Bioservices and its former parent company, Peregrine
Pharmaceuticals, including the role of senior vice president of
manufacturing. During that time, he was instrumental in launching,
building and growing Avid’s CDMO business and helping the company
diversify its production capabilities. He spent the past five years
serving as an advisor and acting head of biologics production for
Syngene International, a global discovery, development and
manufacturing organization serving the pharmaceutical
industry.
“We are very pleased to welcome Rich back to
Avid and look forward to the important contributions that he will
make to continuing Avid’s record of delivering excellent CDMO
services to our clients,” said Rick Hancock, interim president and
chief executive officer of Avid. “Rich’s extensive history with the
company, combined with his more recent experience working with a
wide range of innovator companies and international biologics
CDMOs, represents a unique, highly specialized skill set that will
be extremely valuable to Avid’s growth and development.”
During his career, Mr. Richieri has also served
as a global advisor for Samsung Biologics’ biosimilar program, as
well as president of Bioserv Corporation, a specialized contract
manufacturing organization. He most recently served as co-founder
of Rubicon Biotechnology, where he was responsible for process
development and manufacturing of the company’s novel therapeutic
candidates. He earned a bachelor’s degree in chemical engineering
from the University of California, Los Angeles and a master’s
degree in chemical engineering from the University of California,
San Diego.
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical products
derived from mammalian cell culture. The company provides a
comprehensive range of process development, high quality CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 25 years of
experience producing monoclonal antibodies and recombinant proteins
in batch, fed-batch and perfusion modes, Avid's services include
CGMP clinical and commercial product manufacturing, purification,
bulk packaging, stability testing and regulatory strategy,
submission and support. The company also provides a variety of
process development activities, including cell line development and
optimization, cell culture and feed optimization, analytical
methods development and product
characterization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jul 2023 bis Jul 2024